Candel Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDCandel Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 161% provides fundamental context to the price action. However, price is extended 28% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.78 | +17.94% | ABOVE |
| 50 SMA | $8.06 | +28.47% | ABOVE |
| 100 SMA | $6.60 | +56.95% | ABOVE |
| 150 SMA | $6.27 | +65.18% | ABOVE |
| 200 SMA | $6.03 | +71.87% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CADL in an uptrend right now?
CADL has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CADL is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CADL overbought or oversold?
CADL's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is CADL outperforming the market?
CADL has a Relative Strength (RS) Rating of 94 out of 99. Yes, CADL is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is CADL in its 52-week range?
CADL is trading at $10.36, which is 100% of its 52-week high ($10.38) and 100% above its 52-week low ($4.35).
How volatile is CADL?
CADL has a Beta of 1.97 and 52-week volatility of 73%. It's more volatile than the S&P 500 - expect bigger swings.